These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 28589759

  • 21. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
    Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Naim A, Parasuraman S, Boyle J, Mascarenhas JO.
    Cancer; 2017 Feb 01; 123(3):449-458. PubMed ID: 27690182
    [Abstract] [Full Text] [Related]

  • 22. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A.
    Semin Hematol; 1999 Jan 01; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [Abstract] [Full Text] [Related]

  • 23. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP, Sanchez SR, Ewton AA, Rice L, Perkins SL, Dunphy CH, Chang CC.
    Hum Pathol; 2008 Oct 01; 39(10):1454-8. PubMed ID: 18619646
    [Abstract] [Full Text] [Related]

  • 24. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
    Greenberg PL.
    Clin Haematol; 1986 Nov 01; 15(4):973-93. PubMed ID: 3552351
    [No Abstract] [Full Text] [Related]

  • 25. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.
    Verstovsek S, Yu J, Scherber RM, Verma S, Dieyi C, Chen CC, Parasuraman S.
    Leuk Lymphoma; 2022 Mar 01; 63(3):694-702. PubMed ID: 34689695
    [Abstract] [Full Text] [Related]

  • 26. A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera.
    Hernández-Boluda JC, Pereira A, Cervantes F, Alvarez-Larrán A, Collado M, Such E, Arilla MJ, Boqué C, Xicoy B, Maffioli M, Bellosillo B, Marugán I, Amat P, Besses C, Guillem V.
    Blood; 2012 May 31; 119(22):5221-8. PubMed ID: 22496165
    [Abstract] [Full Text] [Related]

  • 27. Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience.
    Begna K, Abdelatif A, Schwager S, Hanson C, Pardanani A, Tefferi A.
    Blood Cancer J; 2016 May 27; 6(5):e427. PubMed ID: 27232929
    [No Abstract] [Full Text] [Related]

  • 28. Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm.
    Molitor DCA, Boor P, Buness A, Schneider RK, Teichmann LL, Körber RM, Horvath GL, Koschmieder S, Gütgemann I.
    Ann Hematol; 2021 Jan 27; 100(1):97-104. PubMed ID: 33104881
    [Abstract] [Full Text] [Related]

  • 29. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S, Hubmann E, Porwit A, Bjorkholm M, Hoefler G, Beham-Schmid C.
    Arch Pathol Lab Med; 2014 Sep 27; 138(9):1203-9. PubMed ID: 25171702
    [Abstract] [Full Text] [Related]

  • 30. Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia.
    Suleiman Y, Dalia S, Liu JJ, Bowers JW, Padron E, Lancet JE, Fulp W, Moscinski LC, Komrokji RS, Zuckerman KS, Zhang L.
    Leuk Res; 2016 Mar 27; 42():52-8. PubMed ID: 26894965
    [Abstract] [Full Text] [Related]

  • 31. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients.
    Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C.
    Acta Haematol; 1991 Mar 27; 85(3):124-7. PubMed ID: 2042444
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Leukemia and related disorders.
    Anderson RE.
    Hum Pathol; 1971 Dec 27; 2(4):505-14. PubMed ID: 5286449
    [No Abstract] [Full Text] [Related]

  • 34. Inflammation and myeloproliferative neoplasms.
    Lussana F, Rambaldi A.
    J Autoimmun; 2017 Dec 27; 85():58-63. PubMed ID: 28669446
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
    Kvasnicka HM, Thiele J.
    Semin Thromb Hemost; 2006 Jun 27; 32(4 Pt 2):362-71. PubMed ID: 16810612
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent.
    Higuchi T, Okada S, Mori H, Niikura H, Omine M, Terada H.
    Cancer; 1995 Jan 15; 75(2):471-7. PubMed ID: 7812918
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.